Clinical Factors Influencing the Compliance With National Head and Neck Cancer Targets in the United Kingdom: Results From a National Cohort Study

Clinical Otolaryngology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 11, 2025

ABSTRACT Introduction In the United Kingdom, it is standard of care that treatment decisions in all new cases head and neck cancer (HNC) are discussed at a multidisciplinary team meeting (MDT). The aim this project was to gain national perspective on scope current HNC treatment, compliance with pathway targets, their influence survival outcomes. Methods A multicentre, retrospective, observational study primary patients specialist MDT between September November 2021. Results Data 1488 were included from 50 UK departments. most common subsite oropharynx (35.4%, 522), which 61.7% (263) HPV positive. Median time referral diagnosis, decision first definitive HNCs managed curatively 37 (interquartile range [IQR] 22–57), 42 (IQR 29–65), 74 54–101) days, respectively. Compliance 28‐day, 31‐day, 62‐day targets met 32.8% (488), 33.3% (495), 34.6% (515), On multivariate analysis, urgent referrals, T1–T2 stage disease, not undergoing general anaesthetic biopsy associated greater targets. Conclusion This highlights majority delays seen points journey. Improving adherence best practice standards will contribute reducing for HNC.

Язык: Английский

BAG3 Positivity as Prognostic Marker in Head and Neck Squamous Cell Carcinoma

Cancers, Год журнала: 2025, Номер 17(11), С. 1843 - 1843

Опубликована: Май 31, 2025

Background: Head and neck squamous cell carcinoma (HNSCC) exhibit considerable heterogeneity, complicating the prediction of disease progression treatment response. Consequently, researchers are actively investigating reliable biomarkers to forecast trajectories inform therapeutic decisions. This study examines role BAG3, a protein involved in survival stress response, as potential predictive marker HNSCC. The objective is analyze BAG3 expression across various HNSCC types correlate it with disease-free (DFS), aiming elucidate influence positivity on cancer progression. Methods: A multi-institutional retrospective was conducted by analyzing immunohistochemistry 104 tissue samples from patients head (HNSCC). data were then correlated DFS assess impact prognosis. Results: Immunohistochemical analysis primary tumor collected therapy-naive showed that widespread different sites, no significant correlation sex, smoking status, HPV infection, location, grade, or TNM parameters. However, high positive had shorter (median 23.2 months) compared BAG3-negative 31.3 months). Cox revealed IHC associated more than 3-fold increased risk recurrence. Conclusions: first explore biomarker for While preliminary findings suggest link between recurrence risk, further research needed validate these results. Prospective studies could help establish BAG3’s prognostic value potentially lead personalized approaches

Язык: Английский